ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q1 2024 Earnings Call Transcript September 14, 2023
ImmunoPrecise Antibodies Ltd. misses on earnings expectations. Reported EPS is $0.11 EPS, expectations were $0.17.
Operator: Good morning, ladies and gentlemen. Thank you for joining us today for IPA’s Earnings Call covering the First Quarter of Fiscal Year 2024. I am Julianne, and I have the privilege of hosting this call. Before we commence, I would like to draw your attention to the fact that our discussion today may include forward-looking statements. These statements are subject to various risks and uncertainties that could cause actual results to differ materially from what we express or imply. We strongly encourage you to review our filings with the Securities and Exchange Commission for a comprehensive discussion of these risks and uncertainties. IPA remains committed to complying with legal requirements and will update forward-looking statements only as mandated by law.
Pressmaster/Shutterstock.com
During today’s conference call as well as in the accompanying presentation slides, we will be employing non-GAAP financial measures to assist investors and analysts in comprehending IPA’s business performance. Adjusted EBITDA in particular allows for meaningful comparisons and analysis of trends in our business over different periods. For a detailed explanation and reconciliation of these non-GAAP measures to GAAP measures, please refer to managements discussion and analysis section of our filings on EDGAR and SEDAR. Now without further ado, I would like to pass the floor over to IPA’s CEO, Dr. Jennifer Bath, who will provide an overview of our quarterly results.
Jennifer Bath: Great. Thank you, Julianne, and good morning, everyone. I’d like to extend a heartfelt welcome to all of you for joining us this morning on our earnings call. Your time and your interest, as always, in ImmunoPrecise Antibodies is deeply valued. The past two quarters have posed significant challenges for our company, our management and our investors. Despite these hurdles, we have initiated transformative changes that will be pivotal in driving our growth. These aren’t merely temporary adjustments. They mark profound resurgence as we evolve to be more resilient with a unified strategy. The unwavering strength and support from our diverse and expanding team have charted a renewed path for IPA. This direction is as defining to our legacy as the inception of our B-cell platform, our strategic acquisitions and our transition to the NASDAQ Global Market.
As we turn the page on a significant chapter in IPA’s history, we are poised to embark on a unified vision of modernization, technological transformation and unwavering commitment to excellence. We are elated to announce the esteemed addition of Chris Buyse, Dr. Barry Springer and Dirk Witters to our Board of Directors as on September 5. Chris Buyse, renowned for his pivotal roles in companies like Inventiva, Hyloris Pharmaceuticals, brings a wealth of experience in capital raising endeavors. His insights will fortify our financial strategies, no doubt, anchoring us firmly on the path to enduring growth. Dr. Barry Springer, a distinguished figure with notable affiliations at Johnson & Johnson, Merck and Abbott is the driving force behind Springer Bio-Tech Consulting.
His tenure as former Vice President of Janssen Strategy, Operations and Innovation has equipped him with unparalleled expertise in therapeutic antibody discovery and development. Furthermore, his leadership role in shaping Janssen BioTherapeutics platform, technology strategy and licensing, showcases his depth of knowledge and vision. Dr. Springer extensive background in drug and technology and licensing will play a crucial role in refining our strategic direction. Dirk Witters, the visionary founder of Conanti Consult not only boast over two decades of experience with KBC Group in Corporate and Investment Banking, but also exemplified leadership as the CEO of KBC France. His profound knowledge in capital raising, acquisitions and executive leadership will be instrumental in propelling ImmunoPrecise Antibodies to greater heights.
With the combined acumen and foresight of our new Board members, we are invigorated about the boundless growth potential of ImmunoPrecise Antibodies. Their collective expertise promises to amplify our trajectory, ensuring we are not only – we not only surmount upcoming challenges, but we also harness the vast opportunity that is awaiting us. Despite the challenges we have faced, I’m pleased to report that we had a very positive financial quarter, demonstrating our second back-to-back quarter of record revenue and establishing a new record for quarterly revenue. To be specific, our consolidated revenue grew 21.3% year-over-year. In addition, we saw our protein manufacturing facility make strategic use of its newly expanded facilities, demonstrating an impressive growth of 44% year-over-year.
As we will expand on shortly, our record revenue was met with significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million. Another positive back-to-back quarter trend. Lastly, we are happy to state that our quarterly burn slowed to CAD1.6 million in this first quarter. These results mark continued growth in the face of headwinds that have presented challenges within the life sciences market in general. We believe that our success in this quarter is a testament to the resilience and dedication of our management team as well as the robustness of our contract research services. We remain committed to delivering value to our shareholders and are hopeful about the opportunities that now lie ahead.
We are excited to update our valued shareholders on two significant developments that are integral to the new and promising strategic vision being tracked by our new Board members and management. First, we have filed an F-3 form with the SEC move that allows us to register securities for a shelf offering, a move that makes it easier for us to attract U.S. investors and access U.S. capital markets. This strategic action is part of our ongoing effort to strengthen our financial position and set the stage for the successful implementation of our unified strategic vision. We believe these steps will greatly benefit IPA and our shareholders as we embark on this new invigorated journey. Thank you once again for joining us today. We look forward to sharing more details about our performance and our plans during this call.
I’ll now turn the microphone over to Dr. Barry Duplantis for updates on client relations and business development.
Barry Duplantis: Yes. Thank you, Jennifer. As discussed during our recent 2023 fiscal year-end earnings call, the diligent efforts of our fiscal year 2023 sales initiatives are now bearing fruit in fiscal 2024 revenue figures. We are delighted to report a remarkable 21.3% year-over-year Q1 growth in revenue. And once again, this growth has been predominantly propelled by exceptional performance of our protein expression services and our industry-leading B-cell select platform. Moreover, our focus on sales orders, which is a recurring highlight of our earnings discussions, has yielded exceptional results once again. We have observed a significant year-over-year Q1 increase of 59%, primarily attributed to an outstanding sales performance in the month of June, which stands as the highest in IPA history.
In specific terms, June sales orders of $3.51 million represented an impressive 125% surge compared to June of fiscal year 2023. The positive trend continued into July with sales orders reaching $1.56 million, marking a substantial 64% increase over July of fiscal year 2023. I’d also like to remind the audience, the sales orders are primarily composed of antibody discovery programs as the majority of our protein expression revenue bypass this financial step. We maintain a high level of confidence in our future prospects, driven by the combined momentum of new BioStrand-base fee-for-service discovery programs and our upcoming participation in fall conferences. These conferences will provide an excellent platform to showcase our seamlessly integrated wet lab and in silico capabilities.
This strategic alignment positions us well to sustain this robust growth trajectory. As discussed during our previous earnings calls, the partnership between BioStrand and BriaCell is in its final phase, compromising wet lab evaluation of the output of the in silico work. We completed the wet lab analysis and are currently compiling the data for reporting to BriaCell. And with that, I would like to hand it over to our Chief Scientific Officer.
Ilse Roodink: Yes. Thank you, Barry. Good morning, everyone. I’m pleased to delve into our recent strategic advancements and ongoing research initiatives with you all. Over the past quarter, we have honed our service packages, emphasizing the synergy between our lab techniques and computational methodologies. This fusion is particularly pivotal due to the early phases of therapeutic development. While traditional methods have served us well, our evolved approach leverages above algorithms and data analytics, aiming for a more streamlined and potentially cost-effective process. Our infrastructure allows us to efficiently and seamlessly manage multiple projects concurrently amplifying the potential value for our clients. We are gearing up to showcase the synergistic power of computational technology and high-quality laboratory research to form the selection of functional derisked antibodies.
During the speaker presentation in the AI and computational Discovery and Development Presentation track at the Festival of Biologics in Basel this October. Alongside this, we will be touring key European hubs, interacting with industry thought leaders and elucidating the capabilities of our latest platforms. In a collaborative stride with BioStrand, we have fine-tuned our service offerings to accelerate and optimize therapeutic lead nomination by integration of developed and cynical prediction technologies for epical billing of target identification and screening alongside in silico risk assessment into our well-respected laboratory services. This spectrum encompasses hands-on lab services augmented with AI-driven computational solutions. Our commitment remains unwavering as we continually adapt to the dynamic scientific landscape.
Our B-cell discovery technology also have taken a leap forward. We’ve incorporated robotized method, enabling precise electrification of individual B-cells based on their unique functionalities. This automation not only expedited process, but also paves the way for potential treatments that regulate these cellular responses. We are eager to share these insights at the Festival of Biologics in Basel. Bispecific sector is on an accelerating trajectory, a persistent challenge has been ensuring the structural integrity of molecules. To tackle this, we have been refining our novel purification technique at our facility in Utrecht. This method integrates automation, ensuring consistent and high-quality production of bispecific. Complemented with our expertise, we are poised to cater the burgeoning demand.
Neoantigens, which are elder proteins primarily found on tumor cells have peaked the interest of the medical community. IPA has been focused on developing novel methodologies to detect antibodies that specifically target with neoantigens. Leveraging our bispecific capabilities, we are working towards providing a comprehensive solution for clients keen on exploring this exciting therapeutic avenue. Our journey is characterized by thorough growth and naval adaptation by keeping a pose on industry trends and harnessing our technological expertise aspire to be trendsetters in the realm of accelerated AI-driven biotherapeutic development. I will now turn the microphone over to Dr. Jennifer Bath to provide some operational updates on IPA.
Jennifer Bath: Great. Thank you so much, Ilse. I’d like to share with you today some operational updates, in particular around our artificial intelligence and its integration into our wet lab capabilities. At the heart of our progress, is our commitment to enhancing our AI capabilities, in particular. We have developed a revenue strategy that leverages the power of our unique and patented technology, much of what you’ve heard about in the previous quarterly earnings call. This strategy focuses on combining our digital or in silico services with our renowned laboratory services. First, we are proud to mention that our digital services stand alone and in addition to that offer immense value to both new and existing programs. We are truly excited to showcase these new and distinguished services on-site at corporations throughout Boston and Cambridge for approximately a week long period at the end of this month.
With regard to new platform capabilities, we are excited to say that we’ve recently secured projects utilizing multiple features of our platform, such as predicting the characteristics, safety and effectiveness of antibodies. Given the value of these features can add at various stages of antibody development, we’ve now made them a standard part of our service offering. IPA also now employs a novel digital analysis of antibodies and other proteins, focused on assessing potential clinical risks very early on. We can quickly screen countless antibodies and provide our clients with actionable reports. This in-depth analysis helps our clients make informed decisions about their clinical strategies. BioStrand has already completed several paid projects in this area, paving the way for a consistent revenue with our partners.
Lastly, we are thrilled to introduce a groundbreaking feature in our LENSai platform. Now boasting a cutting-edge combination of our proprietary neuro-symbolic engine and advanced large language models, such as ChatGPT. This breakthrough allows us to answer some of the most challenging questions in life sciences with unparalleled precision and speed with the accuracy and transparency of LENSai and the dialogue function of ChatGPT. The type of questions cover a broad range and can either be general in nature or they can be very specific by the user. Our unique approach ensures accuracy and clarity and addresses the life science industry’s need for both precision and explainability. We’ve already demonstrated early validation with internal research, and we are rolling this service out as we speak.
I’d now like to turn the call over to Brad McConn, our Chief Financial Officer, to give you more insights into our financials from this first quarter.
Brad McConn: Thank you, Jennifer, and good morning, everyone. I’ll provide an overview of our financial results for the year before touching on our financial position as of the end of the period. As a reminder, all numbers I referenced are in Canadian dollars, unless otherwise noted. As we mentioned, IPA recorded total revenue of $5.7 million during the three months ended July 31, 2023, a 21.3% increase compared to the same period last year. Both our protein production and B-cell select platform realized impressive results during the quarter with our Utrecht and Victoria sites growing 44% and 25.5% year-over-year, respectively. Gross profit for the quarter totaled $2.8 million, an increase of $0.3 million compared to the prior year.
While gross profit margin was 49.1% compared to 52.9% in fiscal 2023. Operating expenses totaled $7 million in Q1 as compared to $12.6 million during the same period last year. Research and development expenses totaled $0.4 million, a decrease of $5.7 million compared to fiscal 2023. This decrease is primarily related to a significant reduction in spend on the poly to antibody combination therapy as compared to last year. Research and development expenses during Q1 include $0.3 million in salary costs, including share-based payments that was allocated to research and development, along with $0.2 million in research expense. Sales and marketing expenses totaled $1.1 million during Q1 of fiscal 2024, which represents a small increase of $41,000 compared to the prior year.
Expenditures during the first quarter included $0.8 million in salary costs, including share-based payments that was allocated to sales and marketing, along with $0.2 million in advertising costs. General and administrative expenses totaled $4.6 million during the first quarter as compared to $4.2 million during the same period last year. Increases include $0.1 million in salary costs and $0.1 million in interest recorded on the company’s leases. Finally, amortization of intangibles decreased $0.3 million. As the intangibles recorded in connection with the acquisition of our of location, were fully amortized in the first month of the quarter. Moving on to other income. IPA recorded other income of $0.4 million during the first quarter of fiscal 2024 compared to $0.3 million during fiscal 2023.
Other income included $0.3 million in grant income, $0.1 million in interest and other income and $0.1 million in unrealized foreign exchange loss. All told, IPA recorded a net loss of $3.6 million during the three months ended July 31, 2023 compared to a loss of $9.4 million during the first quarter of last year. Moving on to the balance sheet. IPA has held cash of $6.8 million as of July 31, 2023, compared to $8.4 million as of April 30, 2023, a decrease of $1.6 million during the quarter. If we look at our last five quarters, our burn was $10.6 million during Q1 of fiscal 2023, $5 million during Q2 of last year, $3.7 million in Q3, $3 million in Q4. And finally, as I mentioned, $1.6 million this quarter. During the period, cash used in operating activities totaled $0.7 million.
While cash used in investing activities included $0.1 million in equipment purchases and $0.1 million for a deferred acquisition payment in connection with the BioStrand acquisition. Along with $0.1 million in proceeds from the sale of our investment in QBQ Holdings B.V. Cash used in financing activities included $0.4 million in lease payments. And with that, I’ll turn it back to Julianne for Q&A.
See also 25 Most Admired Companies in 2023 and 10 Best ESG ETFs.
Q&A Session
Operator: Thanks, Brad. Before Jennifer adds any closing remarks, we would like to open the floor to any questions from analysts and investors. Of note with the numerous live and virtual investor conferences this week, several investors and analysts have sent over questions in the past day, which we want to ensure are addressed, if they were not already clearly covered in the script content. In those instances, I will be reading those questions aloud for the members of the IPA management team. [Operator Instructions] And our first question on the phone line comes from Ramakanth Swayampakula from H.C. Wainright. Please go ahead. Your line is open.
Swayampakula Ramakanth: Thank you. Good morning, Jennifer. So a couple of quick questions. Just at a high level, I want to understand how the BioStrand acquisition, now that you have had BioStrand for more than a year now. How are you monetizing it? And also what – when should we expect BioStrand revenues coming from BioStrand to be material?
Jennifer Bath: Hi, RK. Thanks for joining us, and thank you for your thoughtful questions. So first of all, with regard to answering this question, in particular, also for those who may not have been with us at the end of the last fiscal year, earnings call, our most recent earnings call. I’ll first like to point back and reference that fiscal year earnings call where we gave the outline of the three main pillars for monetizing BioStrand and along in addition with that also some milestones with timelines and revenue. As a brief summary here for the audience, for you RK, we have focused on the combined AI and wet lab services as a primary focus for the short-term revenue. And these are the service offerings that also inform and improve LENSai as they’re being utilized for these clients.
That LENSai is at the heart of everything we do, including all of our other pillars and service offerings that we are rolling out. We also again present a longer-term vision for our SaaS model, utilizing the analytical tools and data management to a life science companies and handling massive amounts of data to be organized and managed if they still choose. Also, they can use that to be analyzed using LENSai, and again, LENSai giving them the opportunity for that unparalleled and invaluable insight into these massive amounts of data, which right now at most companies are just being stored and actually costing the company’s money without them being able to use that for analysis. And the other component there was this opportunity for companies to partner with BioStrand or in silico discovery programs, partnering relationships that obviously are invaluable to us because they provide us with a wealth of insight and data for BioStrand for training LENSai, but they also carry with them that opportunity for additional downstream financial payments, in the event that a partner chooses to carry forward with a program.
So with regard to those shorter-term services, as I mentioned, we are really now embarking on a very focused output here where we are going into companies starting at the end of this month, specifically to showcase these services which to date have been available online and presented at a conference. But what we have noticed is an interest in multiple large pharmaceutical companies and midsized biotech companies and really getting to understand more how we compete with a few companies out there that offer these services. We have not given a timeline for when we expect, of course, that material revenue stream from that. But what we can say and kind of echoing back to some of the things that Dr. Duplantis has shared with us here. We’re seeing that increase in interest.
We continue to see queues with groups receiving both quotes and then executing on those to convert to sales orders. So the trend for us with regard to that shorter-term revenue certainly looks quite good. With regard to the SaaS model, we did give us some timelines around that with regard to the commitments that are required for investment in time, we’re really looking at probably 12 to 18 months for the actual launch of the SaaS model. Most of those activities can be done internally by BioStrand on a service offering as well. So we are offering those opportunities for clients who want organization and management, but where we really see that potential for a massive shift in revenue and a major increase in the profit margins associated with that, of course, are around the official launch of that Software-as-a-Service.
So we’re really looking at around 12 to 18 months there and what we have outlined in the fiscal year earnings call was really the five-year trajectory with regard to how much of the market we believe we could corner and what that meant for BioStrand with regard to revenue. So hopefully that answers your question, RK.
Swayampakula Ramakanth: I have one quick question. So very recently as you are just talking about it, the HYFT based in silico screening platform. I’m just trying to understand what sort of inquiries are you getting on this? And if there is at least a project or something that you can give us so that we understand as an example of what ability or what capability that you’re actually providing, which is better than what you used to provide?
Jennifer Bath: Yes, absolutely. So yes, Barry I was going to say – I’ll turn that over to you, but maybe start that – yes, but I’ll start that real quickly with just making sure I tie that into this previous statement that a lot of that is also connected to a lot of the interest we have been getting into this targeted approach as well in the Boston area, specifically in response to many of these companies wanting to see the actual data we’ve produced on these platforms. Absolutely, Barry I will definitely turn it over to you as Head of Sales and Client Relations to give some further insights into those inquiries you receive.
Barry Duplantis: Okay. So we have gained traction, and we are expecting revenue to begin shortly for programs using HYFT based screening. The primary type of increase that we’re getting into this type of offering and BioStrand technologies in general are often based off of biological challenges that cannot or have not been successfully addressed in the wet lab. Examples of the type of programs that we’re looking here or I guess, one of the easiest ones that comes to mind is situations where an in vivo platform for immunization or an in vitro platform for screening, where the targets that our clients are looking for are represented differently in the final stage than they are when we produce them as reagents. So in these traditional wet lab techniques, the gap between the reagent and the final – what the final product has to be is quite different.
So that obviously makes it difficult to create antibodies that specifically target the final confirmational stage. So that’s a lot of where the inquiries are coming, and that’s what the HYFT based screening platform is designed to overcome.
Swayampakula Ramakanth: Thank you, Barry. Thanks for that.
Operator: Thank you for your questions, RK. Our first written question comes from Robert Wasserman from Benchmark Capital, and it reads, what is the current disposition of the Board? And how will that change following the annual meeting? With the pending resignation or non-election of Dr. Kuo, who will be the Chairman?
Jennifer Bath: Great. Okay. Well, thanks, first of all, to Robert Wasserman for providing that question. So first of all, I think what I’d really like to start with there is that the current Board, obviously, it has transitioned here over the last couple of weeks and it’s working very constructively together, very collegially together to ensure that we focus on the strategies that are in line with the company’s highest priority. In addition to that, we are working actively on rejuvenation of the Board for the upcoming AGM. Our focus is on bringing in seasoned professionals who have demonstrated excellence in establishing and steering prosperous companies in pioneering new therapeutic solutions. A good example of that is that Dr. Springer, who has now joined us.